News Headlines
-
Scinai Immunotherapeutics' CDMO Unit Selected By Ayana Pharma To Provide Drug Development And cGMP Manufacturing Services
4/8/2024
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced that Ayana Pharma Ltd. signed a five-year Master Service Agreement (MSA) with the Company's CDMO business unit, Scinai Bioservices.
-
AustinPx Invests In Pharmaceutics And Manufacturing Capabilities To Accelerate Drug Development
4/8/2024
AustinPx, a leading contract development and manufacturing organization (CDMO) specializing in bioavailability enhancement of orally delivered small molecule drug candidates, today announced its acquisition of a 3P Innovations API in capsule filling machine, a FT4 Powder Rheometer, and the STYL’One Nano compaction simulator.
- InvestING In Pharmaceutics And Manufacturing Capabilities 4/5/2024
-
Memel Biotech Launches Advanced Therapy Contract Development And Manufacturing Organization At The New EU Gateway In Lithuania.
4/4/2024
Memel Biotech today announced it has launched a fully integrated advanced therapy development and manufacturing service from its state-of-art facility strategically located for EU markets at the Baltic seaport of Klaipeda, Lithuania.
-
Caris Life Sciences Announces Partnership With Merck KGaA, Darmstadt, Germany To Discover Novel Cancer Targets And Accelerate First-In-Class Antibody Drug Conjugate Development
4/4/2024
Caris Discovery™, the therapeutic research arm of Caris Life Sciences® (Caris), the leading next-generation AI TechBio company and precision medicine pioneer, today announced a multi-year strategic partnership with Merck KGaA, Darmstadt, Germany, which operates its healthcare business as EMD Serono in the U.S. and Canada, to accelerate the discovery and development of first-in-class antibody-drug conjugates (ADC) for cancer patients.
-
Acumen Pharmaceuticals Collaborates With Lonza To Advance Sabirnetug For The Treatment Of Alzheimer’s Disease
4/4/2024
Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), has signed a collaboration agreement with Lonza, a global partner to the pharmaceutical, biotech and nutraceutical markets.
-
RLS Radiopharmacies Partners With Eckert & Ziegler To Expand Production Of Gallium-68-Based Radiopharmaceuticals
4/4/2024
RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced it has expanded its radiopharmaceutical contract development and manufacturing (rCDMO) capabilities by entering into a strategic agreement with global isotope technology leader Eckert & Ziegler.
-
ProMed Pharma Acquires SpineThera Manufacturing Capabilities And An Option To License Intellectual Property
4/3/2024
SpineThera, Inc., a privately held, clinical-stage pharmaceutical company focused on the development of SX600 (a novel formulation of extended-release dexamethasone microspheres for epidural injection for the management of lumbar radicular pain) and ProMed Pharma LLC, a leading contract manufacturer of polymer-based drug releasing dosage forms and combination device components, announced today that ProMed Pharma has acquired SpineThera’s cGMP manufacturing operational assets.
-
Autolomous & BioCentriq Partner To Speed Up Cell Therapy Delivery
4/3/2024
Autolomous, the market-leading developer of critical manufacturing management systems for cell and gene therapies, and BioCentriq, industry-leading clinical-phase Cell Therapy CDMO (contract development and manufacturing organization), today announce a collaboration to digitize and accelerate process development and manufacturing activities.
-
Prozomix And Ginkgo Bioworks Collaborate On Next-Gen Enzyme Development For Sustainable API Manufacturing
4/3/2024
Prozomix, a UK-based biotech company focused on novel biocatalyst discovery and manufacturing, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership.